Exelixis Announces Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology
Exelixis, Inc. (NASDAQ: EXEL) today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology. The publication includes safety data from all 85 patients enrolled in the phase 1 cabozantinib study, and also includes tumor response, genotyping, pharmacokinetic, and pharmacodynamic biomarker data for the 37 patients in the study with medullary thyroid cancer.
Exelixis is currently conducting a phase 3 registration trial of cabozantinib in MTC and, assuming positive results from this registration trial, intends to file a New Drug Application with the U.S. Food and Drug Administration for this indication by the end of 2011.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.